1. Multhoff G, Molls M, Radons J. Chronic Inflammation in Cancer Development. Front Immunol 2011; 2: 98.
2. Mortaz E, Tabarsi P, Mansouri D, et al. Cancers Related to Immunodeficiencies: Update and Perspectives. Front Immunol. 2016; 7: 365.
3. Przekazińska-Boager K, Brzezicka-Ciach U. Zapalenie skórno-mięśniowe jako rewelator choroby nowotworowej. Przegl Dermatol 2014; 101: 40–45.
4. Dasgupta B, Borg FA, Hassan N, et al. Guidelines and Audit Working Group: BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010; 49(1): 186–190.
5. Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sjögren’s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2016; 55(3): 450-460.
6. Turesson C, Matteson E. Malignancy as a comorbidity in rheumatic diseases. Rheum 2013; 52(1): 514.
7. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3): 692–701.
8. Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin. 2015; 31(3): 557-574.
9. Chen Y, Friedman M, Liu G, et al. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine 2018; 101: 78-88.
10. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015; 74(6): 1087-1093.
11. Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2017; 76(3): 497-503.
12. Raaschou P, Simard JF, Asker Hagelberg C, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 2016; 352: i262.
13. Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 2017; 76(2): 386-391.
14. Dreyer L, Cordtz RL, Hansen IMJ, et al. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis 2018; 77(4): 510-514.
15. Wadström H, Frisell T, Askling J. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med 2017; 177(11): 1605-1612.
16. Kim SC, Pawar A, Desai RJ, et al. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019; pii: S0049-0172(18)30589-4.
17. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis 2009; 68(10): 1580–1584.
18. van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72(9): 1496-1502.
19. Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum 2019; 48(5): 911-920.
20. Kong BY, Immaneni S, Paller AS, et al. Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed. J Am Acad Dermatol 2017; 77(4): 758-763.
21. Skomsvoll F, Ostensen M, Baste V, et al. Number of births, interpregnancy interval, and subsequent pregnancy rate after a diagnosis of inflammatory rheumatic disease in Norwegian women. J Rheumatol 2001; 28(10): 2310–2314.
22. Grosen A, Bungum M, Christensen LA. Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors. J Crohns Colitis. 2019; 13(5): 564-571.
23. Ramonda R, Foresta C, Ortolan A. Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients. Fertil Steril 2014; 101(2): 359-365.
24. Tristano AG. Impact of rheumatoid arthritis on sexual function. World J Orthop 2014; 5(2): 107–111.
25. Gaytán M, Morales C, Bellido C, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and ovulation: lessons from morphology. Histol Histopathol 2006; 21(5): 541-556.
26. Clark DA. Anti-TNFalpha therapy in immune-mediated subfertility: state of the art. J Reprod Immunol 2010; 85(1): 15-24.
27. Winger EE, Reed JL, Ashoush S, et al. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009; 61(2): 113-120.
28. Önalan G, Tohma YA, Zeyneloğlu HB. Effect of etanercept on the success of assisted reproductive technology in patients with endometrioma. Gynecol Obstet Invest 2018; 83(4): 358-364.
29. Micu MC, Micu R, Surd S, et al. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology 2014; 53(7): 1250–1255.
30. Puchner R, Danninger K, Puchner A, et al. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 2012; 30(5): 765–767.
31. Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 2017; 10(6): 661-669.
32. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014; 43: 78-84.
33. Komaki F, Komaki Y, Micic D, et al. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 2017; 76: 38-52.
34. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75(5): 795-810.
35. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76(6): 960-977.
36. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75(1): 3–15.